Monthly Archives: February 2015

Friday 27 February, 2015

Sorry, this entry is only available in  Français.

Posted in Synthèse de presse | Comments closed

VEGF-C, an indispensable growth factor for producing new neurons

Research studies bringing together Inserm, CNRS and Université de Pierre et Marie Curie researchers from the Brain and Spinal Cord Institute in collaboration with a team from the Yale Cardiovascular Research Center, have demonstrated the importance of factor VEGF-C in the activation of neural stem cells, and hence in the production of new neurons.

Posted in Press releases, Neurosciences, cognitives sciences, neurology and psychiatry | Tagged | Comments closed

European Patent Office rankings for 2014: Inserm 6th in France for patent applications, 1st in Europe for patent applications in biomedical research

Inserm, with the help of its subsidiary Inserm Transfert, continues to rise in the 2014 rankings of French patent applicants issued by the European Patent Office (EPO)

Posted in Press releases, Institutional and special event | Tagged | Comments closed

Thursday 26 February, 2015

Sorry, this entry is only available in  Français.

Posted in Synthèse de presse | Comments closed

Saturday 28 February: World rare disease day

A disease is said to be rare if it affects fewer than 1 in 2,000 people, or, for France, fewer than 30,000 people for a given disease.

Posted in In the media, World day | Comments closed

Wednesday 25 February, 2015

Sorry, this entry is only available in  Français.

Posted in Synthèse de presse | Comments closed

Tuesday 24 February, 2015

Sorry, this entry is only available in  Français.

Posted in Synthèse de presse | Comments closed

Preliminary results of the JIKI clinical trial to test the efficacy of favipiravir in reducing mortality in individuals infected by Ebola virus in Guinea.

Preliminary data from the JIKI clinical trial, which is testing the efficacy of favipiravir in reducing mortality associated with Ebola, provide two important pieces of information:
• absence of efficacy in individuals who arrive at treatment centres with a very high level of viral replication and who already have serious visceral involvement,
• and encouraging signs of efficacy in individuals arriving at treatment centres with a high or moderate level of viral replication, who have not yet developed overly severe visceral lesions.
With this classification into two groups, we have a much better understanding of Ebola virus disease, and can redefine the role of antiviral monotherapies in the therapeutic arsenal used against the disease.
The trial, sponsored by Inserm and funded by the European Commission from the Horizon 2020 Initiative under the project title REACTION, is supported by two NGOs, Médecins Sans Frontières/Doctors Without Borders (MSF) and Alliance for International Medical Action (ALIMA); two laboratory networks, Belgian First Aid and Support Team (B-FAST) and European Mobile Laboratory (EMLab); the French Red Cross, and the French Military Health Service.
These preliminary data are being presented on Wednesday 25 February as a late-breaking abstract at the CROI international conference (Conference on Retroviruses and Opportunistic Infections) in Seattle.

Posted in Press releases, Immunology, inflammation, infectiology and microbiology, Public health | Tagged | Comments closed

Long-term consequences of stress experienced in childhood

Exposure to stress during sensitive periods of development in childhood could alter the functioning of the various physiological systems and affect health in the long term.

Posted in News in brief, Public health | Comments closed

Monday 23 February, 2015

Sorry, this entry is only available in  Français.

Posted in Synthèse de presse | Comments closed
fermer
fermer
RSS Youtube